| Name | Title | Contact Details |
|---|
Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada`s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada`s largest database of medical cannabis patients. The company`s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.
Sameday Health is dedicated to healthcare as a complete experience, not simply a service. Our purpose is to create healthcare that centers around the client, combining a human approach with intuitive technology. We offer quality, personalized care wherever you are including in our clinics or at your door.
Alivation puts you and your family`s health and well-being first. We do this by investing in the latest medical advancements and meticulously staffing the foremost experts in our industry. From basic behavioral health and family health services to in-depth treatments via transcranial magnetic stimulation therapy (TMS) and brain network monitoring, Alivation`s world-class facility and personal approach to your care is second to none. With a full-service pharmacy and research team on-site, Alivation is the only integrated healthcare clinic in the area that`s large enough to provide a high standard of unique care while being small enough to know our patients on a personal level.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Carondelet Health Network is composed of Four Hospitals in Southern Arizona and numerous clinics.